Year Founded
2018
Ownership
Private
Employees
~50
Therapeutic Areas
Rare DiseasesOncology
Stage
Commercial
Modalities
Small molecule

QED Therapeutics General Information

FDA approved TRUSELTIQ (infigratinib) for previously-treated locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion. In development for achondroplasia and hypochondroplasia. Phase 2 study showed 23% objective response rate in cholangiocarcinoma.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Palo Alto, California
United States

Drug Pipeline

infigratinib
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to QED Therapeutics's pipeline data

Book a demo

Key Partnerships

Helsinn Group, LianBio

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

QED Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view QED Therapeutics's complete valuation and funding history, request access »

QED Therapeutics Investors

BridgeBio Pharma
Investor Type: Venture Capital
Holding: Minority